• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Monte Rosa Therapeutics Inc (NQ: GLUE )

    8.900 +0.400 (+4.71%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Monte Rosa Therapeutics Inc

    < Previous 1 2 3 4 Next >
    Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis
    The companies will collaborate on a molecular glue degrader, a potential treatment for autoimmune diseases. 
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    “Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”
    Via AB Newswire
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Monte Rosa Therapeutics: Q4 Earnings Insights
    Via Benzinga
    Why Is Monte Rosa Therapeutics Stock Surging On Monday?
    Monte Rosa Therapeutics stock rises as it announces a global licensing deal with Novartis to advance MRT-6160 for immune conditions. 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Beats Revenue for Q2 2024
    GLUE stock results show that Monte Rosa Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Monte Rosa Therapeutics Announces Leadership Team Promotions
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Misses Revenue for Q1 2024
    GLUE stock results show that Monte Rosa Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer
    Dr. Wallace will depart his role as CSO effective May 17, 2024, and will serve as a scientific advisor, including on Monte Rosa’s Scientific Advisory Board 
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter loss. Westport Fuel Systems posted a quarter loss of 81... 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    GLUE Stock Earnings: Monte Rosa Therapeutics Misses EPS for Q4 2023
    GLUE stock results show that Monte Rosa Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.